GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kronos Bio Inc.
Kintara is a biotech company whose stock price reflects its long and difficult history of clinical failures. The chart exemplifies the high risks of biotech, where the company is trying to find its way after these setbacks.
Share prices of companies in the market segment - General oncology therapy
Kronos Bio is a biopharmaceutical company focused on developing drugs that target transcription factors for the treatment of cancer. We have classified it in the "General Oncology" category. The chart below shows how the market values companies working on this new class of oncology drugs.
Broad Market Index - GURU.Markets
Kronos Bio is an oncology company developing drugs that target transcription factors that control cancer cell growth. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Kronos shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
KRON - Daily change in the company's share price Kronos Bio Inc.
For Kronos Bio, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Kronos Bio is a biopharmaceutical company focused on developing drugs targeting transcription factors for the treatment of cancer. Oncology is a highly volatile sector. The chart below shows average fluctuations in this industry, providing context for evaluating KRON shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Kronos Bio is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kronos Bio Inc.
Kronos Bio, Inc.'s year-over-year performance is a story about the development of its oncology drugs targeting transcription factors. Its 12-month market cap is entirely dependent on clinical trial data. The success of its CDK9 inhibitors could offer a new approach to treating blood cancers, its primary research bet.
Annual dynamics of market capitalization of the market segment - General oncology therapy
As an early-stage biotech company, Kronos Bio is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kronos Bio, a biopharmaceutical company focused on transcription factor-targeted drugs for cancer treatment, operates at the forefront of science. Its annual market capitalization performance is driven by progress in its complex clinical programs and is unrelated to macroeconomic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kronos Bio Inc.
Kronos is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its targeted drugs triggers an immediate and strong investor reaction.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
This chart reflects the dynamics of the biotech sector, particularly in oncology. For Kronos, a clinical-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in cancer treatments are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kronos Bio is a clinical-stage biotech company developing cancer treatments. Its value depends almost entirely on the results of clinical trials. The broader market has little impact on Kronos Bio's stock; its fate is decided in laboratories and clinics, which can lead to sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kronos Bio Inc.
Kronos Bio is a clinical-stage oncology company. Its weekly stock price, like that of other biotech companies, is entirely dependent on news about the progress of clinical trials of its transcription factor-targeted drugs.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Kronos Bio is a biotech company developing drugs for difficult-to-treat cancers by targeting transcription factors. This is a cutting-edge scientific approach. The chart will show whether Kronos's stock price fluctuations are driven by its unique scientific data or reflect the overall sentiment of investors in the oncology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kronos is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
KRON - Market capitalization of the company Kronos Bio Inc.
Kronos Bio's market capitalization dynamics reflect investors' faith in its scientific approach to cancer treatment, based on gene transcription regulation. As a clinical-stage company, its stock price is highly volatile and driven by news about its research progress. It's a high-risk bet on cutting-edge oncology.
KRON - Share of the company's market capitalization Kronos Bio Inc. within the market segment - General oncology therapy
Kronos Bio is an oncology company focused on developing drugs for difficult-to-treat cancers. Its market share in the pharmaceutical sector is small, reflecting its clinical-stage status. Its market capitalization reflects investors' assessment of its scientific approach and the potential of its research portfolio.
Market capitalization of the market segment - General oncology therapy
The chart below shows the overall value of the biotech sector. Kronos Bio is a company focused on developing cancer drugs that target transcription factors. This is a highly complex but also highly promising area. Kronos's story, compared to the market, exemplifies how fundamental science is being translated into real-world treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kronos Bio is an oncology company developing drugs that target transcription factors that control cancer cell growth. Its market capitalization is a bet on this new scientific approach. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
KRON - Book value capitalization of the company Kronos Bio Inc.
Kronos Bio's foundation is its scientific platform for developing drugs targeting transcription factors long considered "drug-proof." This chart tells the story of a biotech company investing in a complex and high-risk scientific approach to cancer treatment.
KRON - Share of the company's book capitalization Kronos Bio Inc. within the market segment - General oncology therapy
Kronos Bio develops drugs against difficult-to-treat cancers. The chart shows its share of actual R&D assets. These include its laboratories researching transcription factors, which provide the scientific foundation for a new approach to oncology.
Market segment balance sheet capitalization - General oncology therapy
Kronos Bio is a biopharmaceutical company specializing in oncology. Their focus is on clinical research rather than manufacturing. A book value chart shows their modest R&D base, as their main asset is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Kronos Bio's balance sheet includes laboratories and R&D centers developing drugs targeting transcription factors for cancer treatment. The chart shows how the company built its scientific and material foundation for its clinical programs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kronos Bio Inc.
Kronos Bio is a biotech company focused on difficult-to-treat cancers. Its assets are its scientific platform. The chart below is a barometer of faith in its developments. Market capitalization, like many companies in this field, reflects potential future success, not the current asset value.
Market to book capitalization ratio in a market segment - General oncology therapy
Kronos Bio is a biotech company focused on developing cancer treatments that target transcription factors—hard-to-reach targets. Its valuation is based on the potential of its scientific platform. The chart shows the premium its market capitalization represents over its current assets.
Market to book capitalization ratio for the market as a whole
Kronos Bio is a biotech company focused on oncology. Its value is determined by its pipeline of promising developments. This chart illustrates that its market capitalization reflects investor confidence in the success of its scientific approach, rather than the valuation of its tangible assets, which is typical for innovative biotechs.
Debts of the company, segment and market as a whole
KRON - Company debts Kronos Bio Inc.
Kronos Bio is a clinical-stage biotech company focused on developing drugs for difficult-to-treat cancers. This chart illustrates its financial model. The company uses significant capital raised through its IPO to fund its complex and expensive clinical trials.
Market segment debts - General oncology therapy
Kronos Bio is a biotech company focused on developing drugs for difficult-to-treat cancers. Its scientific approach requires extensive research and significant funding. This chart shows the company's financial needs during its long journey from the lab to potential drug approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kronos Bio Inc.
Kronos Bio is a clinical-stage oncology company. This chart shows its financial structure. For a biotech whose future depends on the success of clinical trials, debt is a huge risk. A failure in research could make it impossible to finance.
Market segment debt to market segment book capitalization - General oncology therapy
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing cancer treatments. This chart shows the debt burden in the biotech sector, a key indicator of the company's ability to fund its expensive research and development in this highly competitive field.
Debt to book value of all companies in the market
Kronos Bio is a clinical-stage oncology company focused on drugs that target transcription factors. This is a fundamental approach to cancer treatment. This graph of total market debt serves as an indicator of investor risk appetite, which directly impacts the company's ability to fund its advanced research.
P/E of the company, segment and market as a whole
P/E - Kronos Bio Inc.
Kronos Bio is a biotechnology company focused on developing drugs that target transcription factors for the treatment of cancer. This graph reflects the high risks and potential associated with this innovative scientific approach. The development is entirely dependent on clinical trial results.
P/E of the market segment - General oncology therapy
Kronos Bio is a clinical-stage biotech company focused on developing drugs that target transcription factors—proteins that control gene expression and are often implicated in cancer. This chart shows the average valuation for the oncology therapeutics sector, reflecting how investors value companies attacking cancer at a fundamental level.
P/E of the market as a whole
Kronos Bio is a biotech company specializing in cancer drug development. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kronos Bio Inc.
Kronos Bio is a biotechnology company focused on developing cancer drugs that target transcription factors that control gene expression. This graph reflects market expectations for the success of its innovative scientific approach. Future revenue is dependent on clinical trial results.
%20P%2FE%20Kronos%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kronos-Bio-Inc.&v=1772582972566 "Chart of the company's future (projected) P/E Kronos Bio Inc.")
Future (projected) P/E of the market segment - General oncology therapy
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing drugs that target transcriptional regulatory networks in cancer. The chart reflects average expectations for the oncology segment. KRON's position relative to this benchmark reflects investor assessment of its cutting-edge scientific approach to treating difficult-to-treat cancers.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772582972598 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing drugs that target transcription factors for the treatment of cancer. This is a fundamental approach to the fight against cancer. This chart of overall market expectations shows how willing investors are to fund complex scientific platforms with long development cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772582972613 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kronos Bio Inc.
Kronos Bio is a clinical-stage biotechnology company focused on developing drugs that target transcription factors for the treatment of cancer. Its financial schedule is driven by research expenses. Potential profitability depends on the success of this innovative approach in oncology.
Profit of companies in the market segment - General oncology therapy
Kronos Bio is a clinical-stage biopharmaceutical company developing drugs targeting transcription factors historically considered "untreatable." This chart shows the overall profitability of the oncology sector. It reflects the willingness of investors to fund breakthrough, yet risky, scientific approaches to cancer drug development.
Overall market profit
Kronos Bio is a biotechnology company developing drugs targeting transcription factors for the treatment of cancer. This is a complex and cutting-edge field of science. The company's success depends on the results of its clinical programs. The overall market situation, reflected in this chart, affects its ability to attract capital to fund expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kronos Bio Inc.
Kronos Bio is a clinical-stage biopharmaceutical company developing cancer drugs targeting transcription factors. This chart reflects analysts' speculative expectations regarding the potential of this new scientific approach, which could open new avenues for cancer treatment.
%20profit%20of%20the%20company%20Kronos%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kronos-Bio-Inc.&v=1772582972840 "Graph of future (projected) profit of the company Kronos Bio Inc.")
Future (predicted) profit of companies in the market segment - General oncology therapy
Kronos Bio is a biotech company developing cancer treatments targeting transcription factors previously considered "drug-resistant." The company's future depends on the success of its innovative platform. This chart reflects forecasts for the entire biotech sector, providing context for assessing the potential and risks of Kronos Bio's cutting-edge approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772582972843 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Kronos Bio is a biotech company focused on developing oncology drugs. Its current value is determined not by revenue, but by the potential of its scientific research. Therefore, its performance is weakly correlated with overall economic trends, as illustrated by this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772582972871 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kronos Bio Inc.
Kronos Bio is a clinical-stage biotech focused on oncology. Its high valuation, visible on this chart, is based on the potential of its scientific platform targeting transcription factors. Its performance is entirely dependent on the success of its drug candidates in clinical trials.
P/S market segment - General oncology therapy
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing treatments for cancers caused by transcriptional dysregulation. Future revenue is dependent on the success of these developments. This oncology chart reflects investor expectations for Kronos Bio's innovative scientific approach.
P/S of the market as a whole
Kronos Bio is a clinical-stage biotechnology company focused on developing drugs for difficult-to-treat cancers by targeting transcription factors. This market revenue valuation chart helps understand how investors view this complex and cutting-edge scientific approach in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kronos Bio Inc.
Kronos Bio is a clinical-stage biotechnology company focused on developing drugs that target transcription factors for the treatment of cancer. This chart shows how the market perceives the future commercial potential of its scientific approach. It reflects investor expectations for the success of its clinical programs.
%20P%2FS%20Kronos%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kronos-Bio-Inc.&v=1772582972915 "The graph of the company's future (projected) P/S Kronos Bio Inc.")
Future (projected) P/S of the market segment - General oncology therapy
Kronos Bio is a clinical-stage biotechnology company focused on developing drugs that target transcription factors—proteins that control gene expression—for the treatment of cancer. The company's valuation is based on investors' belief in its cutting-edge scientific approach, which could unlock new ways to fight cancer.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772582972951 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Kronos Bio is a clinical-stage biotech company focused on treating difficult-to-treat cancers. Its prospects depend on the success of its research. In the context of the overall revenue projections shown in the chart, Kronos represents a venture investment in the future of oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772582973051 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kronos Bio Inc.
Kronos Bio is a clinical-stage oncology company focused on developing drugs that target cancer-causing transcription factors. The company currently has no commercial products and does not generate revenue from sales.
Sales of companies in the market segment - General oncology therapy
Kronos Bio (KRON) is a biotechnology company focused on developing drugs for difficult-to-treat cancers by targeting transcription factors that regulate gene expression. This metric reflects revenue in the oncology sector. Kronos Bio's innovative approach targets the fundamental mechanisms that govern cancer cell growth.
Overall market sales
Kronos Bio is a biotech company developing drugs targeting transcription factors that play a role in cancer development. Its growth depends on scientific advances. This pattern of overall economic activity influences the investment climate. During favorable periods, biotech companies find it easier to attract capital for research in complex areas of oncology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kronos Bio Inc.
Kronos Bio is a biotechnology company focused on developing drugs that target transcription factors for the treatment of cancer. Its future revenue depends on the success of clinical trials of its targeted oncology drugs. This chart reflects analyst forecasts, which assess the potential of its innovative scientific platform.
%20sales%20of%20the%20company%20Kronos%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kronos-Bio-Inc.&v=1772582973160 "Schedule of future (projected) sales of the company Kronos Bio Inc.")
Future (projected) sales of companies in the market segment - General oncology therapy
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing transcription factor-targeted drugs for the treatment of cancer. This graph shows the potential future revenue from their pipeline of candidates. This is an analyst's view of the commercial prospects of their scientific approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772582973178 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Kronos Bio is a biotechnology company focused on developing cancer drugs that target transcription factors previously considered inaccessible to therapy. This approach is cutting-edge. This graph reflects the overall investment climate, and Kronos Bio's progress is a bet on fundamental science, which could unlock new ways to fight cancer.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772582973261 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kronos Bio Inc.
Kronos Bio is a clinical-stage biotechnology company developing drugs targeting transcription factors for the treatment of cancer. Its financial performance reflects significant investment in this complex scientific field. The chart shows the current profitability as an investment in the development of a new class of anticancer drugs.
Market segment marginality - General oncology therapy
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing drugs that target transcription factors for the treatment of cancer. This chart reflects its operating expenses. Future profitability depends on the success of its sophisticated scientific approach and clinical programs.
Market marginality as a whole
Kronos Bio is a clinical-stage biotechnology company focused on developing drugs for difficult-to-treat cancers. This total return chart reflects the investment climate. For companies operating at the forefront of science, access to capital is critical, and it becomes easier during periods of overall economic health.
Employees in the company, segment and market as a whole
Number of employees in the company Kronos Bio Inc.
Kronos Bio is a biopharmaceutical company developing drugs targeting transcription factors—proteins that control gene expression and often play a key role in cancer development. This graph shows the team working on this new and complex approach to cancer drug development.
Share of the company's employees Kronos Bio Inc. within the market segment - General oncology therapy
Kronos Bio is a clinical-stage biotechnology company focused on developing cancer drugs by targeting transcription factors. This is a complex area of oncology. This chart shows the highly skilled team of scientists the company has assembled to implement its unique scientific approach and translate it into new treatments.
Number of employees in the market segment - General oncology therapy
Kronos Bio is a biopharmaceutical company focused on developing drugs that regulate cancer-causing genes. This chart, showing its involvement in oncology therapy, illustrates the company's search for new fundamental approaches to treatment. For Kronos, with its focus on transcriptional regulation, growth in this area demonstrates recognition of the importance of its scientific platform.
Number of employees in the market as a whole
Kronos Bio is a biotech company specializing in drugs that target transcription factors for cancer treatment. This is a fundamental scientific approach. Funding for such long-term research is possible in a strong economy. The growth in overall employment, reflected in this chart, is a sign of such an environment, attracting capital to cutting-edge science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kronos Bio Inc. (KRON)
Kronos Bio (KRON) is a biotech company focused on oncology. This biotech chart is an indicator of concentrated value. Market capitalization is based on expectations for clinical trials and patent value. A small team of scientists can create an asset worth billions.
%20of%20the%20company%20Kronos%20Bio%20Inc.%20(KRON)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kronos-Bio-Inc.-KRON&v=1772582973510 "Chart of market capitalization per employee (in thousands of dollars) of the company Kronos Bio Inc. (KRON)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Kronos Bio is a biopharmaceutical company focused on oncology. Its value is determined by its pipeline of potential drugs. This chart demonstrates the high future value the market attributes to its clinical development pipeline, based on its relatively small team of scientists and managers.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772582973540 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Kronos Bio is a biotech company focused on developing cancer drugs that target transcription factors. This approach is fundamental science. This chart for Kronos Bio illustrates how biotech companies operating at the very edge of scientific knowledge can have colossal market capitalization per employee, reflecting their belief in their scientific breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772582973567 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kronos Bio Inc. (KRON)
Kronos Bio is a biotech R&D company focused on oncology. The company is profitless. This graph will show a negative value—the loss per employee. This reflects the amount of capital the company burns through clinical research.
%20Chart%20Kronos%20Bio%20Inc.%20(KRON)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kronos-Bio-Inc.-KRON&v=1772582973594 "Company Profit Per Employee (in thousands of dollars) Chart Kronos Bio Inc. (KRON)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Kronos Bio is a biotechnology company focused on developing drugs for difficult-to-treat cancers. In oncology, the productivity of a research team is a key asset. This chart shows the financial return per employee, which helps investors evaluate the efficiency of capital deployment on the path to drug discovery.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772582973599 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Kronos Bio is a biotech company focused on developing cancer treatments that target transcription factors (key gene regulators). This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772582973612 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kronos Bio Inc. (KRON)
Kronos Bio is a clinical-stage biotech company focused on developing cancer treatments. Because it has no commercial products yet, revenue per employee is minimal or nonexistent. This chart clearly illustrates the R&D phase, where all value is generated through oncology research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kronos-Bio-Inc.-KRON&v=1772582973631 "Sales chart per company employee Kronos Bio Inc. (KRON)")
Sales per employee in the market segment - General oncology therapy
Kronos Bio (KRON) is a biotech company specializing in the development of cancer treatments that target transcription factors. This chart shows the average income per employee in the sector. It is important for assessing R&D efficiency and personnel structure compared to other oncology biotechs.
Sales per employee for the market as a whole
Kronos Bio (KRON) is a clinical-stage biotechnology company focused on developing drugs that target transcription factors (complex proteins that control genes) for the treatment of cancer. The company has no commercial revenue. This near-zero metric reflects the high cost of R&D and maintaining a team of elite scientists.
Short shares by company, segment and market as a whole
Shares shorted by company Kronos Bio Inc. (KRON)
Kronos Bio (KRON) is a clinical-stage biotech company focused on oncology. This chart shows short interest. The high bearish bets reflect the inherent risks of biotech: concerns about clinical trial failure, high cash burn, and fierce competition in cancer drug development. (337)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kronos-Bio-Inc.-KRON&v=1772582973717 "Short Shares Chart for the Company Kronos Bio Inc. (KRON)")
Shares shorted by market segment - General oncology therapy
Kronos Bio (KRON) is a biopharmaceutical company focused on developing drugs against difficult-to-treat cancers by targeting transcription factors. The chart below shows a general short position in the oncology biotech sector, reflecting investor skepticism about the success of fundamental research.
Shares shorted by the overall market
Kronos Bio (KRON) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like KRON in favor of safer assets that generate profits here and now.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kronos Bio Inc. (KRON)
This chart for Kronos Bio shows binary bets in oncology. The company is targeting complex targets (transcription regulators) for cancer treatment. "Overbought" levels (above 70) arise from positive early-phase trial data. Clinical failure or the announcement of program closure immediately sends the oscillator into "oversold" levels (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kronos-Bio-Inc.-KRON&v=1772582973803 "RSI 14 indicator chart for the company's stock Kronos Bio Inc. (KRON)")
RSI 14 Market Segment - General oncology therapy
Kronos Bio (KRON) is a biotech company attacking cancer through gene "regulators." This is complex, fundamental science. This chart measures overall sentiment in the Oncology sector. It helps distinguish KRON's clinical data-driven dynamics from the overall "overheated" or "oversold" sentiment in the biotech sector.
RSI 14 for the overall market
For Kronos Bio, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KRON (Kronos Bio Inc.)
Kronos Bio is a biotech company focused on oncology. It develops drugs targeting transcription factors that control cancer. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of the company's R&D portfolio and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KRON-Kronos-Bio-Inc.&v=1772582973954 "A chart showing analyst consensus forecasts for the expected stock price. KRON (Kronos Bio Inc.)")
The difference between the consensus estimate and the actual stock price KRON (Kronos Bio Inc.)
Kronos Bio (KRON) is a biotech company focused on developing cancer treatments by targeting transcription (the process of reading DNA). This chart shows the difference between the market valuation and the consensus forecast. It highlights the potential (and risks) analysts see in this complex R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KRON-Kronos-Bio-Inc.&v=1772582974005 "A chart showing the difference between the consensus forecast and the actual stock price. KRON (Kronos Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Kronos Bio (KRON) is a biotech company targeting one of the roots of cancer: deregulated transcription factors that drive tumor growth. This chart reflects the collective opinion of analysts on the *entire* oncology R&D sector. It shows whether experts believe a breakthrough can be achieved against these fundamental drivers of cancer.
Analysts' consensus forecast for the overall market share price
Kronos Bio is a biotech company specializing in the development of targeted therapies for cancer treatment. This chart shows the overall market "risk appetite." For KRON, a high-risk clinical-stage company, overall market optimism (the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kronos Bio Inc.
Kronos is a biotech R&D company focused on precision oncology. Their signature R&D platform (inhibitors) targets genes (transcription) that cause blood cancer (leukemia). This chart is a pure R&D barometer of faith/fear. It doesn't reflect sales, but rather the market's speculative valuation of their (very risky) pipeline and clinical data.
AKIMA Market Segment Index - General oncology therapy
Kronos Bio is an oncology company focused on intractable targets. They are developing drugs against cancer transcription factors—proteins previously thought to be untreatable. This chart compares their composite index to their sector, showing how their overall oncology portfolio compares to others.
The AKIM Index for the overall market
Kronos Bio is a biotech company focused on targeted cancer therapies that target transcription factors. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this pipeline-redefining scientific story stacks up against broader economic trends.
